Feature|Articles|November 16, 2026

The Hidden Risk in Pharma’s AI Rush

Author(s)Dan Barton
Listen
0:00 / 0:00

Key Takeaways

  • Mounting AI spend reflects a pivot away from primary research, but “spend-first, measure-later” adoption can create downstream brand-performance gaps when market behavior is inferred rather than observed.
  • Launch and competitive-response decisions require current, indication-specific behavioral insights that are neither public nor extractable from claims; AI without fresh evidence amplifies inference, not truth.
SHOW MORE

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.

Pharmaceutical firms are under more pressure than ever to expand R&D productivity, increase sales, and cut costs. At the same time, everyone is chasing opportunities in big data, advanced analytics, and AI. But there's a risk in the rush. Overreliance on AI, or removing human oversight for speed, can create systemic problems. The question isn't whether to use AI, but whether we are using it for sustainable value or short-term efficiency gains that create systemic problems later.

AI isn't neutral. These models reflect the biases present in the information they were trained on. In pharmaceuticals, where decisions are expensive to reverse, inputs are everything. While AI speeds up analysis, competitive advantage comes from unique data, not commoditised models. If we look at many of the pharma marketing trends of the past, failures can most often be traced back to the idea that technology was viewed as a substitute for understanding prescriber behavior.

AI may ultimately prove more transformative than any of those shifts. That's precisely why getting the operating model right matters. The current wave carries a familiar risk, only faster. Healthcare AI spending nearly tripled from an estimated $480 million in 2024 to $1.4 billion in 2025. Anecdotal signals suggest a meaningful share of that spend is shifting from proven primary research towards internal builds, synthetic data, and increasingly sophisticated models on the argument that AI can serve as a substitute for physician, patient, and payer research. Yet replacing primary research with synthetic data or internal AI builds remains largely unproven. The risk is simple: spend first, measure later, and discover the gap in brand performance.

Redefining decision-making

Consider the questions that brand teams need answered to make a launch call, respond to a competitive entry, or defend a resource allocation: How is a specialist reasoning through a narrow indication right now? How does a biologic-experienced patient weigh a treatment switch? Where does a payer stand on a newly approved agent this quarter not last year?

That information isn't published anywhere, and it isn't sitting in a claims feed waiting to be scraped. A general-purpose model can synthesise what's already public, but it can't manufacture behavioural evidence that doesn't yet exist. It can tell you what a market looked like last year, and not why prescribing has shifted over the last six months among the specialists who matter to your brand. That kind of evidence has to be gathered directly from the field, kept current, and generated independently from the public and manufacturer sponsored information that increasingly forms the common knowledge base available to company sponsored AI systems. And one part of this is structural, not a matter of degree: at launch, there's no historical data to synthesise. A more powerful model operating without evidence doesn't create evidence, it creates a more sophisticated inference.

That distinction matters. AI is extraordinarily good at finding, connecting, synthesizing, and interrogating information. But it is not inherently an evidence-generation system. When the question is what physicians, patients or payers actually think and do today, somebody still has to create the evidence.

The role of synthetic data

Synthetic data has real uses like extending existing evidence, simulating scenarios, filling gaps and stress testing hypotheses. What it cannot do on its own is establish new empirical evidence about how real physicians, patients, or payers are behaving today. In our research, the surprise is often the whole point: the physician whose reasoning breaks the pattern, the patient barrier the existing evidence didn't predict, or the market shift that becomes visible only when new data are collected. Ask synthetic data to carry a launch decision alone, and you're still reasoning from what was already known.

While it generates ideas, primary research tests them against market reality. Relying solely on synthetic data risks a recursive loop of analysing closed information, whereas primary research introduces vital new observations.

Setting the standard

In January 2026, the FDA and EMA jointly issued Guiding Principles on Good AI Practice in Drug Development, emphasising data quality, validation rigour, and human oversight. We're not in drug development ourselves, but the direction is the same: even in the highest-stakes corner of pharma AI, regulators are converging on the standard I'd hold our own team to, regardless of what they require of us specifically: I want to know what the model is reasoning from, who reviewed the output, and who's accountable if it's wrong. We establish documented workflows for how AI is used in client-facing processes, including where expert review and accountability sit. Every AI-assisted output at Spherix passes through a human expert before it reaches a client. Not because technology can't be trusted, but because human expertise isn't simply the last quality-control step. It determines which questions are worth asking, which signals deserve scrutiny, what the evidence can and cannot support, and what a finding actually means for a brand. Judgement matters most when the stakes and ambiguity are highest.

AI as an enabler

This isn't a case against AI. It's a case for using it towards long-term value instead of simply for efficiency gains. By automating the mechanical work, such as data wrangling, first-pass synthesis and pattern-surfacing across years of studies - AI allows time to reinvest in deeper reflection, richer inputs, and sharper judgement on consequential decisions.

Get this right, and the next five to ten years look genuinely different: AI clears the mechanical burden, allowing experts to focus on interpretation and decision quality, while insights move at the speed of the market. AI can find patterns, connect evidence, generate hypotheses and accelerate interpretation. But primary research with physicians, patients and payers establishes what is actually happening in the market and gives those systems something new to learn from. Competitive advantage won't come from AI, proprietary data, or human expertise alone. It will come from combining all three: differentiated evidence others can't simply prompt their way into, technology that extracts more value from it and experts who understand what the evidence means.


Related to this article